The results of our Annexin V assay demonstrate that while the KRAS WT CRC cells show no significant increase in apoptosis (p > 0.05), after 60 h of 10 μM PRMT5 inhibitor treatment, the KRAS mutant CRC cells showed a significant 10.0% (p < 0.05) increase in apoptosis. This evidence concerns the gene PRMT5 and colorectal carcinoma.